Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Bifidobacterium longum strain NCIMB 41676 improves sleep.

Abstract: Methods of treating a subject by administering Bifidobacterium longum strain NCIMB 41676 are discussed. The method may include orally administering a formulation comprising Bifidobacterium longum strain NCIMB 41676 to improve sleep.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Bifidobacterium longum strain NCIMB 41676 improves sleep.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

Abstract: In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA: 5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradrenaline reuptake, such as pain predominant-type depression, depression secondary to chronic or neuropathic pain, and neuropathic pain itself.

Abstract: In accordance with the present invention, it has been discovered that pindolol provides a highly effective treatment for PMS and/or PMDD. As such, the present invention generally relates to methods and compositions for treating and/or preventing PMS, or symptoms associated therewith including premenstrual tension or premenstrual dysphoria. The methods and compositions of the invention also involves the use of pindolol, a known beta adrenergic blocker, in combination with known contraceptives.

Abstract: In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA:5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradreanaline reuptake, such as ADHD, CFS, fibromyalgia, and depression with pain.

Abstract: A method of treating a disorder characterized by hypothalamic-pituitary-adrenal axis over-activity comprising administering to a subject a probiotic bacterium.

Abstract: In accordance with the present invention, it has been unexpectedly found that the administration of an acetylcholinesterase inhibitor in combination with a tricyclic antidepressant having anti-muscarinic properties provides a highly effective and well tolerated treatment for nicotine dependence and dementias, such as Alzheimer's disease (AD). In one aspect, it is effective in the treatment of nicotine dependence, as well as in the treatment and mitigation of nicotine withdrawal symptoms and in the effectuation of smoking cessation. In another aspect, it is effect in the treatment and mitigation of dementias such as Alzheimer's disease.

Abstract: The present invention relates to compositions and methods for treating depression. The compositions and methods comprise the use of anti-inflammatory compounds alone or in combination with antidepressant compounds to down regulate HPA activation through the targeting of peripheral (non-CNS) cytokines.

Abstract: A method of treating a disorder characterized by hypothalamic-pituitary-adrenal axis over-activity comprising administering to a subject a probiotic bacterium.